Kornimate/medical-research-clean huggingface dataset:
cardiotoxicity in locally advanced lung cancer patients treated with chemoradiation therapy

Conditions: Cardiotoxicity; Lung Cancer Stage III; Lung Cancer Stage II; Radiation Toxicity

Summary: this observational cohort will evaluate the cardiovascular effects of chemoradiation used to treat locally advanced, non-small cell lung cancer. patients will be enrolled prior to the start of therapy and followed during and for at least 2 years after therapy with echocardiograms, nuclear stress tests, blood sampling, and quality of life surveys.

lung cancer is both the most common malignancy worldwide and the leading cause of cancer death in the us. while radiation therapy is highly effective for many solid tumors, thoracic radiation therapy carries a risk of cardiovascular morbidity and mortality that limits critical gains in cancer control and survival. the investigators will perform detailed cardiovascular phenotyping using biologic and imaging markers to define functional and physiologic perturbations that occur with radiation therapy. the study will provide insights into how cardiovascular risk factors and disease impact these biologic and functional changes. the investigators will also determine which radiotherapy dose-volume metrics are indicative of subclinical cardiotoxicity.

Eligibility criteria:
inclusion criteria: * at least 18 years of age * histologically confirmed or clinically diagnosed non-small cell lung cancer where the plan is for definitive treatment that includes radiation * able to give written informed consent exclusion criteria: * pregnant or breast-feeding * prior treatment with anthracyclines * radiation treatment not expected to involve any heart exposure as determined by treating provider * ecog performance status greater than 2 * vulnerable patients, including pregnant women and prisoners * contraindication to rest/vasodilator stress pet/ct, including: asthma with ongoing wheezing at time of enrollment; known mobitz type ii av block, 3rd degree av block, or sick sinus syndrom, without a pacemaker; systolic blood pressure less than 90mmhg; known hypersensitivity to regadenoson and adenosine; profound sinus bradycardia (heart rate less than 40bpm).

Keywords: radiation therapy cardiotoxicity cardiovascular risk factors lung cancer cardiovascular phenotyping radiation therapy cardiovascular disease cardio-oncology
a study of positron emission tomography (pet) with [89]zr-df-iab2m in patients with high-risk prostate cancer

Conditions: Prostate Cancer

Summary: this is a prospective, multicenter, open-label, non-randomized study evaluating the ability of \[89\]zr-df-iab2m to detect local, regional and metastatic prostate cancer confirmed by pathology.

iab2m is an approximately 80 kda molecular weight antibody fragment (a "minibody") chelated with desferroxamine and radiolabeled with \[89\]zr. \[89zr\]-df-iab2m targets the extracellular domain of prostate membrane specific antigen (psma) expressed on most primary and metastatic prostate cancer lesions. this is a phase 2, prospective, multi-center, open-label, non-randomized study evaluating the ability of \[89\]zr-df-iab2m to detect local, regional and metastatic prostate cancer confirmed by pathology in patients with biopsy-proven prostate cancer thought to be candidates for radical prostatectomy and pelvic lymph node dissection who are at high-risk for pelvic lymph node metastasis. these patients may have identified lymphadenopathy on conventional imaging but are considered eligible if still judged to be candidates for radical prostatectomy and lymph node dissection.

Eligibility criteria:
inclusion criteria: 1. histological diagnosis of prostate adenocarcinoma. 2. patients considered candidates for radical prostatectomy and pelvic lymph node dissection. these patients may or may not have identified nodal metastasis on conventional imaging but would still be candidates for radical prostatectomy and pelvic lymph node dissection. 3. patients, who are at high-risk for pelvic lymph node metastasis as defined by a lymph node involvement risk of greater than or equal to 20% using the briganti nomogram. 4. age ≥ 18 years. 5. ability to understand and willingness to sign irb approved consent form 6. for men of child-producing potential, the use of effective contraceptive methods during the study. exclusion criteria: 1. treatment or plans for treatment with radiation therapy, surgery, chemotherapy, or investigational therapy between the time of conventional imaging, \[89\]zr-df-iab2m pet/ct and the surgical resection or biopsy procedures used for the study evaluation. 2. unwillingness or inability to comply with procedures required in this protocol. 3. other cancers that might potentially interfere with the reading and interpretation of \[89\]zr-df-iab2m pet/ct scans. 4. patients who are currently receiving any other investigational agent. 5. patients who have had or are currently receiving androgen deprivation therapy
big data construction and biological etiological epidemiology study of children epilepsy in china

Conditions: Epilepsy

Summary: the purpose of this study is to develop the electronic management platform for children with epilepsy, establish large data of chinese children with epilepsy and explore its biological etiology.

the establishment of the electronic management platform for children with epilepsy and large data of epilepsy in chinese children as well as the epidemiological study its biological etiology.

Eligibility criteria:
inclusion criteria: * children with epilepsy diagnosis, seizure types and causes of disease classification in accordance with the international association for the diagnosis and treatment of epilepsy in 2015 guidelines * epilepsy children included 0-14 years old from outpatients and inpatients by the children's epilepsy specialist using igrowsys management platform and clinical research, and medical records data entry complete in all china exclusion criteria: * the patients that recorded data is not complete, telephone and communication address unknown * the patients that families do not have internet or children and families will not access the internet, can not be online operation

Keywords: electronic management of epilepsy biological etiology chinese children
genetic study of families with high frequency of hodgkin lymphoma

Conditions: Hodgkin Lymphoma

Summary: hodgkin lymphoma (hl) is a relatively rare disorder with known familiar aggregation (i.e. hl in more than one child, or parent and child). because affected individuals in familial hl are genetically related, the existence of such families has long been considered as evidence in support of a genetic basis of hl susceptibility. however, it is largely unknown which genetic variations are responsible for recurring hl in families. because the effects of genetic variants are likely to be strong in familial hl, identification of such variations will potentially reveal biological pathways critical to the pathogenesis of hl. primary objective: * to perform genome-wide sequencing of families with recurring hodgkin lymphoma cases (affected as well as non-affected family members) to identify potential disease-causing germline genetic variations. secondary objective: * to describe demographic and clinical features of the affected families.

this study entails a clinical interview and submission of a peripheral blood or saliva sample for non-tumor dna. participants diagnosed with hl at outside institutions will be requested to sign a release form to allow the outside institution to send their pathology report confirming their hl diagnosis. if available, previously banked tumor tissue samples will be utilized to assess genetic alterations related to hl. detailed history will be obtained (e.g., demographics, environmental exposures, cancer risk factors, and family pedigree) to facilitate the analysis of phenotype-genotype correlations, taking into account potential confounding factors. investigators will examine the germline and possibly the tumor dna of each individual participant and use the data from all participants to determine if a gene change is related to hl.

Eligibility criteria:
inclusion criteria: * patient with hl diagnosed ≤ 21 years of age with a first-degree relative also diagnosed with hl. * family members of the patient, either affected or unaffected by a malignancy who agree to participate in the study. * research participant or legal guardian, as appropriate, must provide informed consent for this protocol. exclusion criteria: * inability or unwillingness of research participant or legal guardian/representative to give written informed consent.

Keywords: genetic studies pediatric
safety and efficacy study of exc 001 to improve the appearance of scars from prior breast surgery

Conditions: Scar Prevention

Summary: this study will compare how well exc 001 works to improve the appearance of scars in subjects undergoing breast scar revision surgery. the study will also evaluate the safety of exc 001 in healthy adult subjects.


Eligibility criteria:
inclusion criteria: * subjects must have previously had breast surgery resulting in unacceptable scars * subject has chosen to have the breast scars revised * subjects must not be pregnant or lactating exclusion criteria: * currently pregnant or pregnant during the 6 months prior to inclusion in the study, or lactating * participation in another clinical trial within 30 days prior to the start of the study * any other condition or prior therapy, which, in the opinion of the pi, would make the subject unsuitable for this study

Keywords: scarring cicatrix fibrosis pathologic process
prevalence of fid and qol in patients with oncological and with haematological malignancies

Conditions: Functional Iron Deficiency

Summary: prospective single-center observational study assessing prevalence of fid (laboratory work-up) and quality of life (questionnaire) in adult patients with oncological and with haematological malignancies within four weeks prior to disease-directed therapy.

patients included into the study will have a laboratory work-up assessing the occurence of functional iron deficiency using laboratory parameters (full blood count, reticulocytes, transferrin saturation, serum-ferritin, crp, alat) and have to fill in once the fact-an questionnaire generating data on quality of life at time of study entry.

Eligibility criteria:
inclusion criteria: * age \> 18 years * patients with oncological (solid tumors) and with haematological malignancies (non-solid tumors, including plasma cell myeloma, lymphoma, myeloproliferative neoplasias \[mpn\], myelodysplastic syndromes \[mds\] and chronic leukemias) * within four weeks prior to disease-directed systemic therapy * participation in other trials is possible exclusion criteria: * known iron deficiency with or without iron substitution p.o. or i.v. within last 8 weeks prior to inclusion into this trial * therapy with rbc-transfusions within last 8 weeks prior to inclusion into this trial * therapy with esa within last 8 weeks prior to inclusion into this trial * malignancies with acute need for therapeutic intervention (e.g. acute leukemias, superior vena cava obstruction, etc.) * pregnancy * any other serious underlying medical, psychiatric, psychological, familial or geographical condition, which in the judgment of the investigator may interfere with the trial * inability to give consent
pediatric headche assessment using hit 6

Conditions: Headache Disorders, Primary

Summary: the study is a prospective cohort study. the study population will include 100 children aged 6-18 years suffering from headaches who visited the pediatric neurology clinic at bnai zion medical center and completed both the ped-midas and hit-6 questionnaires, starting from november 2022 until the end of the study period. data will be collected from medical records and from the two questionnaires completed by the children during their clinic visit.

abstarct background: headache is one of the most common complaints in children and adolescents and is a leading cause of functional impairment in teenagers and young adults. the most common primary headaches being migraine and tension-type headache. headaches negatively impact children\&#39;s lives in various ways, with the effect varying according to the severity of the pain, the duration of the attack, and the response to treatment. to assess the degree of impact of headaches on daily functioning, the ped-midas questionnaire was developed, tested, and validated in children aged 4-18 years, however, children often face difficulties in completing the questionnaire. the hit-6 questionnaire, on the other hand, is user friendly however is validated only for adults. research objectives: to compare the ped-midas and hit-6 questionnaires in their ability to assess the degree of impact of headaches on daily functioning. research methods: the study is a prospective cohort study. the study population will include 100 children aged 6-18 years suffering from headaches who visited the pediatric neurology clinic at bnai zion medical center and completed both the ped-midas and hit-6 questionnaires, starting from november 2022 until the end of the study period. data will be collected from medical records and from the two questionnaires completed by the children during their clinic visit. research importance: children often struggle with completing the ped-midas questionnaire because it requires them to recall the number of days their functioning was impaired over the three months prior to completing the questionnaire. this may lead to inaccurate completion and, consequently, an assessment that does not reflect the true impact. this created the need to compare the ped-midas with the hit-6 and examine whether it can serve as a better alternative.

Eligibility criteria:
inclusion criteria: * chldern age 6-18 years with headache for at least 3 months. * children able to fill the questionnaire exclusion criteria: * children with shoreter headaches. * children who are not able to fill the questionnaire

Keywords: headache migraine assessment pedmidas hit 6
auricular percutaneous electrical nerve field stimulation for postoperative pain control in adults

Conditions: Pain, Postoperative

Summary: pain after surgery is unavoidable, and opioid medications are the cornerstone of most pain management regimens. however, they come at a cost with profound impacts on gastrointestinal motility, respiratory depression, and even long-term dependence. stimulating the external ear with cutaneous electrical current is similar to acupuncture and could help improve postoperative pain. the bridge device (manufactured by key electronics \[jeffersonville, in, usa\] and distributed by innovative health solutions \[versailles, in, usa\]), has been used with success in treating opioid withdrawal and in animal studies has shown increases in pain thresholds. the investigators propose a prospective, randomized, placebo-controlled, double-blinded trial to evaluate if auricular neurostimulation improves postoperative pain and reduces opioid requirements for patients undergoing elective colon surgery. pain perception in post-operative patients may be modulated via the auricular branch of the vagus nerve. this has the potential to reduce the use of opioid medications, which will in turn reduce the incidence of postoperative ileus and reduce patient need for and dependence on narcotic pain medications. this would have an enormous economic impact due to decreased length of hospital stays for patients who undergo abdominal surgery. in addition, opioid reduction could potentially lessen the national crisis of opioid addiction.


Eligibility criteria:
inclusion criteria: * elective colon surgery * age over 18 years * provide informed consent exclusion criteria: * emergency surgery * history of opioid dependence/use, anxiety with anxiolytic use * planned icu admission postoperatively * adhesive allergy/sensitivity * other medical contraindications

Keywords: colorectal surgery transcutaneous electric nerve stimulation
cognitive bias modification (cbm) via imagery and internet cognitive behavioural therapy (icbt) for depression

Conditions: Depression

Summary: a randomised controlled trial comparing internet based cognitive behavioural therapy for major depressive disorder plus a cognitive bias modification intervention (oxigen) version a vs. internet based cognitive behavioural therapy for major depressive disorder plus a cognitive bias modification intervention (oxigen) version b on symptoms of depression and negative interpretation bias.

cognitive accounts of depression and anxiety emphasize the importance of cognitive biases in the maintenance of disorders. one specific bias is the interpretation of ambiguous information. a negative interpretation bias is defined as a systematic tendency to interpret potentially ambiguous information in a negative rather than benign way and this bias has been associated with symptoms of depression. research has led to the recent development of computerized cognitive bias modification (cbm) techniques to augment such biases and it has been suggested that cbm techniques may be useful as an adjunct to current treatments to enhance maintenance of treatment gains and minimize relapse rates. the fact that cbm procedures lend themselves to being delivered remotely, are cost-effective, and can be self-paced in ways that suit the patient make them an ideal candidate for inclusion in the internet-based cognitive behavioural therapy (icbt) programs currently offered through st. vincent's hospital and the university of new south wales. therefore, the primary aim of the current trial is to evaluate the acceptability and effectiveness of adding cbm procedures to the existing icbt modules offered through st. vincent's hospital and the university of new south wales. it is expected that icbt + cbm (active version) will result in superior treatment outcomes as indexed by a standardized clinical battery compared to icbt + cbm (control version).

Eligibility criteria:
inclusion criteria: * meet diagnostic and statistical manual of the american psychiatric association - 4th edition (dsm-iv) criteria for major depressive disorder * internet and printer access * australian resident * fluent in written and spoken english exclusion criteria: * current substance abuse/dependence * psychotic mental illness (bipolar or schizophrenia) * change in medication or psychological treatment during last 1 month or intended change during study duration * use of benzodiazepines * severe depression (phq9\> 23) * suicidal
an educational program about abdominal compartment syndrome

Conditions: Intraabdominal Hypertension

Summary: early detection of intra-abdominal hypertension is essential to the prevention of abdominal compartment syndrome and requires close surveillance of intra-abdominal hypertension in patients at increased risk. intra-abdominal hypertension measurements are often taken by the bedside nurse, and in some cases, initiation of serial intra-abdominal hypertension monitoring is prompted by critical care nurses.

measurement of intra-abdominal pressure is simple, inexpensive, safe and accurate method in determining the presence of intra-abdominal hypertension. this measurement can guide patient management. monitoring intra-abdominal pressure and abdominal per-fusion pressure. for signs of abdominal compartment syndrome has become an inexpensive and useful diagnostics tool for identifying complications. an integrated approach to screening and monitoring for intra-abdominal hypertension may improve patient outcomes and decrease hospital costs. due to the high incidence of intra-abdominal hypertension and abdominal compartment syndrome, it is essential for critical care nurses to regularly monitor intra-abdominal pressure and abdominal per-fusion pressure. critical care nurses have the ability to identify intra-abdominal hypertension and abdominal compartment syndrome, implement and evaluate management interventions. nursing practice should be centered on evidence based practice guidelines . nurses should provide a standard of care in managing patients who are at risk of intra-abdominal hypertension and abdominal compartment syndrome from pre hospital, emergency, operating room and intensive care areas

Eligibility criteria:
inclusion criteria: * all nurses that have more than one years experience in the trauma ,general and gastrointestinal icu exclusion criteria: * nurses less than one year experience
t.e.a. study three days ertapenem versus three days ampicillin- sulbactam

Conditions: Intra-Abdominal Infection

Summary: the aim of the study was to compare the activity (efficacy and safety) of ertapenem administered according to a short treatment for three days versus a short treatment for three days with as in patients with an community acquired iai of mild to moderate severity.

the study project is a prospective, randomized controlled investigation. the study will be performed in the department of transplant, general and emergency surgery of st orsola-malpighi university hospital (bologna, italy), a large teaching institution, with the participation of all surgeons who accept to be involved in. the study is designed and conducted in compliance with the principles of good clinical practice regulations. the tolerability and efficacy of a 3 days treatment with ampicillin- sulbactam (as 3g x 3/ day i.v.) is compared a 3 days regimen with ertapenem (1 g/day i.v.). in patients with localized peritonitis with a blinded evaluation of efficacy end points. evaluation of cure or failure is blinded by use of designated third party individuals who are unaware of the treatment assigned to the patients.

Eligibility criteria:
inclusion criteria: adult patients ( \> 18 years) requiring surgical intervention within 24 hours of diagnosis, for localized iai infections (i.e extending beyond the organ wall but confined near the hollow viscus, mild to moderate in severity): * acute appendicitis: ruptured or perforated with abscess * acute diverticulitis with perforation and/or abscess * acute cholecystitis (including gangrenous) with either rupture or perforation * acute gastric and duodenal ( \> 24 hours) perforation * traumatic (\> 12 hours) perforation of the intestines * secondary peritonitis due to perforated viscus * intra-abdominal abscess (including of liver and spleen) exclusion criteria: * traumatic bowel perforation requiring surgery within 12 hours * perforation of gastroduodenal ulcers requiring surgery within 24 hours * other intra-abdominal processes in which the primary etiology was unlikely to be infectious. * patients lactating or pregnant * patients with a history of allergy, hypersensitivity, or any severe reaction to the study antibiotics * patients with rapidly progressive or terminal illness; * patients with a history or presence of severe hepatic or renal disease (e.g. creatinine clearance \< 0.5 ml/min/1.73 m2); * patients with a concomitant infection that would interfere with evaluation of response to the study antibiotics.

Keywords: localized community acquired intra-abdominal infection (iai) antibiotics localized peritonitis ertapenem
population pharmacokinetics and dosage individualization of paracetamol and ibuprofen in children with pda

Conditions: Patent Ductus Arteriosus

Summary: the investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (pda) and assess the feasibility of dosage individualization.

the investigator's purpose is to study the population pharmacokinetics of paracatamol and ibuprofen in neonates with patent ductus arteriosus (pda) and assess the feasibility of dosage individualization. in this study, the investigator will detect drug concentration in plasma and other clinical test to construct population pharmacokinetic models.

Eligibility criteria:
inclusion criteria: * patients have been diagnosed with pda; * age: postnatal age ≤ 28 days; * paracetamol or ibuprofen used as part of regular treatment; * paracetamol or ibuprofen was administered orally. exclusion criteria: * patients who die within the treatment cycle; * patients with other heart diseases; * other factors that the researcher considers unsuitable for inclusion.